Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 138 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 M1jvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfSbG04PzJiaB?= MoHiSG1UVw>? NGWyb4FKSzVyPUCuNFAxODdizszN M1vYeVE4QTV4MEiw
K562 M{C4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi3NkBp M3SxcGROW09? MoezTWM2OD1yLkCwNUDPxE1? Ml6zNVc6PTZyOEC=
M07e NYL6SXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDmeGFWPzJiaB?= M{TVdmROW09? MVfJR|UxRTBwMECxNkDPxE1? MlPWNVc6PTZyOEC=
ALL3 MlK2R5l1d3SxeHnjJGF{e2G7 MnHFNE4y|ryP M2jVcFczKGh? M4ftN2ROW09? MUTJR|UxRTBwMECwOEDPxE1? NXvsN2dTOTl6OEm1OFA>
CML NWH2NYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ofFIxKG2rbh?= NEXSfWlFVVOR M1\XfmlEPTB;MD6wNFEh|ryP M2fwOFE6OjF7MEG2
BA/F3 NXXYUWpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf5U4M4OiCq NVPNTop[TE2VTx?= MWfJR|UxRTZwNUi5JO69VQ>? Mni1NlMxQDh4NES=
BA/F3 NVfXcWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPBZYU4OiCq NFrVOWlFVVOR NXy1ZVR6UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> MmfmNlMxQDh4NES=
BA/F3 M2rHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3JSpg4OiCq MVvEUXNQ M1vtb2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? MkPuNlMxQDh4NES=
BA/F3 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnlZXY4OiCq NGT0W2tFVVOR M1PicGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?= MnvQNlMxQDh4NES=
BA/F3 NEjDdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HvcVczKGh? NYDsNVlnTE2VTx?= NYfFXlVJUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= NID2Z2czOzNyMUewNy=>
BA/F3 NVjrdWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DzZVczKGh? M4TDemROW09? NHK0S|RKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NHPYWmczOzNyMUewNy=>
BA/F3 NX;IRo1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33ldVczKGh? MoXxSG1UVw>? NYDyenFUUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2= M17VPVI{OzBzN{Cz
BA/F3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rzW|czKGh? NXH4cFIzTE2VTx?= NX\sWFJGUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= Ml3VNlM{ODF5MEO=
BA/F3 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmw[Y44OiCq NH;YTnJFVVOR Mln0TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? M{\WSVI{OzBzN{Cz
BA/F3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC3NkBp MUDEUXNQ NVvQZWh{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? M3TsTFI{OzBzN{Cz
BA/F3 NVXlbo9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfPN4w4OiCq MXjEUXNQ MW\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NX\xOmJ1OjN|MEG3NFM>
BA/F3 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j1WlczKGh? NUnaWXhITE2VTx?= MXvJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> M4HTOlI{OzBzN{Cz
BA/F3 NWnVSVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRO|IhcA>? M33XfGROW09? Mm\PTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NUKzbpBoOjN|MEG3NFM>
T cell MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7yRXY4OiCq MWDEUXNQ M3;1eWlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO Mnr0NVcyPTR3MUK=
WiDr M1;aUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TkXVczKGh? MnPuSG1UVw>? NUTB[4hYUUN3ME2wMlA2OiEQvF2= MVWxOVYyPTVzMh?=
PC3 NYDVPGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[3NkBp MVzEUXNQ Mli5TWM2OD1yLkCwPVQh|ryP MWexOVYyPTVzMh?=
MDA-MB-231 NHf6c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjLO|IhcA>? Ml\OSG1UVw>? MVvJR|UxRTBwMEGyJO69VQ>? NX3sXHdiOTV4MUW1NVI>
Hs578T NEjmNWNEgXSxdH;4bYMhSXO|YYm= NGrHcIc4OiCq MVPEUXNQ MlrrS2k2OD1yLkCzJO69VQ>? NVzaVnprOjRyMUWzNlc>
HMEC MUXDfZRwfG:6aXOgRZN{[Xl? M2rhbFczKGh? MkLtSG1UVw>? NIjj[FdIUTVyPUGuPEDPxE1? M1LhVVI1ODF3M{K3
DU145 NYPOZ3pQS3m2b4TvfIlkKEG|c3H5 MmTYO|IhcA>? MYfEUXNQ NGjJbWZIUTVyPUCuNVYh|ryP MViyOFAyPTN{Nx?=
U251 MYnDfZRwfG:6aXOgRZN{[Xl? MV63NkBp M4SzV2ROW09? M4DJUWdKPTB;Mj64NUDPxE1? MYqyOFAyPTN{Nx?=
NCI60 NYrm[|JmS3m2b4TvfIlkKEG|c3H5 NXLHSmxPPzJiaB?= M{WxdGROW09? NHnlTolIUTVyPUWuO{DPxE1? MW[yOFAyPTN{Nx?=
MALME-3M MWPDfZRwfG:6aXOgRZN{[Xl? M1;lZVczKGh? Mmn3SG1UVw>? MWrHTVUxRTZwNkGg{txO MXWyOFAyPTN{Nx?=
KM12 MnXJR5l1d3SxeHnjJGF{e2G7 MnLrO|IhcA>? MU\EUXNQ NGfEW4xIUTVyPUeuOFQh|ryP MWqyOFAyPTN{Nx?=
SW620 NHzuPFlEgXSxdH;4bYMhSXO|YYm= NUT4SWE1PzJiaB?= NI\jRVZFVVOR MknKS2k2OD16LkSzJO69VQ>? Ml60NlQxOTV|Mke=
RXF 393NL NWr1dGZXS3m2b4TvfIlkKEG|c3H5 NH75U4U1KGSjeYO= M1jVcmROW09? NX\DcJBrUUN3ME2wMlAzOTdizszN MYGyN|I2OzB5NB?=
LXFA 983L M{K2cGN6fG:2b4jpZ{BCe3OjeR?= M1rGfVQh\GG7cx?= NETUc|FFVVOR M2PvVWlEPTB;MD6wOVY2KM7:TR?= MXyyN|I2OzB5NB?=
PRXF DU145 NHLOVW9EgXSxdH;4bYMhSXO|YYm= NELPN|Y1KGSjeYO= NGHhb2xFVVOR M2LQZmlEPTB;MD6wOlI{KM7:TR?= NYLsVXZjOjN{NUOwO|Q>
PAXF 1657L NEK4V|ZEgXSxdH;4bYMhSXO|YYm= Mki4OEBl[Xm| M4rPVWROW09? MmPxTWM2OD1yLkGyNUDPxE1? M4DvblI{OjV|MEe0
CXF 1103L NIfES2REgXSxdH;4bYMhSXO|YYm= MkTJOEBl[Xm| NX7Ie49XTE2VTx?= M{LlRWlEPTB;ND6zOkDPxE1? MlvkNlMzPTNyN{S=
GXF251L NILC[VdEgXSxdH;4bYMhSXO|YYm= MoTpOEBl[Xm| MV;EUXNQ MWXJR|UxRTJwMkWg{txO M3nvW|I{OjV|MEe0
NCI-H23 NX3GWYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDjZW02PzJiaB?= M{HWRWROW09? MkK3TWM2OD1{LkK3JO69VQ>? MXOyN|UzOTB{MB?=
HCT116 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTMRZc4OiCq M2ryZmROW09? MkP5TWM2OD1{LkOg{txO NH\XXo8zOzV{MUCyNC=>
MCF7 NUHYeWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrEeopxPzJiaB?= M1TyTGROW09? MoS3TWM2OD1{LkW3JO69VQ>? NULRXosyOjN3MkGwNlA>
NCI-H460 NWnRfVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK3NkBp NVXjfY1ETE2VTx?= MUjJR|UxRThwOUmg{txO MV:yN|UzOTB{MB?=
DLD1 M2P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPTO|IhcA>? NXzTfJpsTE2VTx?= NXTOdIUxUUN3ME20MlYh|ryP MlHBNlM2Pjd7NkC=
NCI-H661 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TncVczKGh? NH3DSIZFVVOR NWLkNYN4UUN3ME23Mlgh|ryP NEK0dlQzOzV4N{m2NC=>
A549 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\TfIg4OiCq NVHkdZVNTE2VTx?= M2XZWWlEPTB;OD6yJO69VQ>? M2j2eFI{PTZ5OU[w
U937 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLO|IhcA>? M2DRT2ROW09? M1KwVWlEPTB;MUKuNkDPxE1? NHjpcXUzOzV4N{m2NC=>
HEK293 Ml7KSpVv[3Srb36gRZN{[Xl? NWrMVFQ5OTEEoN88US=> NYK2VXh6TE2VTx?= Ml\GTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= M3Xu[lIzPzdyNkGw
HUVEC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHjNE4yPcLizszN NH\4cW04OiCq MoXISG1UVw>? MonnTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN MXeyNlg2Ozl7Mx?=
HUVEC MnrzSpVv[3Srb36gRZN{[Xl? NV\LPXlQOTYEoN88US=> NGSwblU4OiCq NU\iR3pmTE2VTx?= M2T3ZWlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO NHvkXZczOjh3M{m5Ny=>
Plasmodium falciparum M1vse2Z2dmO2aX;uJGF{e2G7 MnfiNVDDqM7:TR?= NWHnWHhvOTVibXnu MoW3SG1UVw>? MoTKTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO NF\PdpYzPDV3MEOzNC=>
PC3 M4T5[GZ2dmO2aX;uJGF{e2G7 MWmwMlEh|ryP NH3Xbok2KGh? M1XwOmROW09? NEjYNZJKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NYnObHZCOTl2NkK5O|U>
DU145 NECzTJNHfW6ldHnvckBCe3OjeR?= MkPPNE4yKM7:TR?= M1LG[VUhcA>? MVPEUXNQ MUDJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= NYXqcnZ4OTl2NkK5O|U>
PC3 NHLFT2RMcW6jc3WgRZN{[Xl? NGP1cXcxNjFizszN M1nSUFUhcA>? NWnYOIJwTE2VTx?= Mki1TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= NWXxXIFYOTl2NkK5O|U>
DU145 MYfLbY5ie2ViQYPzZZk> NUL5SYZjOC5zIN88US=> MUi1JIg> M2rSSWROW09? MWjJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= MWGxPVQ3Ojl5NR?=
PC3 NXvXOXcyU2mwYYPlJGF{e2G7 MnnBNE4yKM7:TR?= M3X6OVUhcA>? MUjEUXNQ MXrJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> M1;oUFE6PDZ{OUe1
DU145 MlXiT4lv[XOnIFHzd4F6 MlyzNE4yKM7:TR?= MnruOUBp NV;tU2NpTE2VTx?= NUPuUXZ1UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= M1vmSlE6PDZ{OUe1
Huh7 MY\BcpRqfmm{YXygRZN{[Xl? MkW5Nk42KM7:TR?= Mn\iOEBl[Xm| M4LKbmROW09? NYP4VZgzUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN MnnpNVc{PjB4N{[=
C6/36 MVnBcpRqfmm{YXygRZN{[Xl? M2fiTVIvPSEQvF2= MmHlOEBl[Xm| M{Hjb2ROW09? NF\3Vo1KdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MWmxO|M3ODZ5Nh?=
U937 M2fiRmZ2dmO2aX;uJGF{e2G7 MWKxJO69VQ>? MoG5NUBp M1XmbWROW09? M3fNdHJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| NXrF[Jc4OTd4OESwPVk>
U937 NWW0dHFVTnWwY4Tpc44hSXO|YYm= M4fqdlEh|ryP NUnEeYFFOSCq MnH4SG1UVw>? NVzBNXY3WmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NFvxRmIyPzZ6NEC5PS=>
murine mast cell MnrXSpVv[3Srb36gRZN{[Xl? M1\pcVEh|ryP MXKyOEBp NUHDVZBsTE2VTx?= NXr4RmpTUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= MlGwNVc3QDRyOUm=
BV-173 NFni[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoruTWM2OD1yLkCwNFAxODFyOTFOwG0> NVfxSoc2W0GQR1XS
K-562 M33JbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3zXYFYUUN3ME2wMlAxODByMEK2OkDPxE1? MoTYV2FPT0WU
BL-70 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn4TWM2OD1yLkCwNFAxODh{MjFOwG0> MX;TRW5ITVJ?
EM-2 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Xe4lKSzVyPUCuNFAxODBzMEig{txO NYfiNHBLW0GQR1XS
LAMA-84 NXrKb2NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{noXGlEPTB;MD6wNFAxODN{MTFOwG0> MYLTRW5ITVJ?
MEG-01 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\1eodKSzVyPUCuNFAxODB7ODFOwG0> NXfQRmVQW0GQR1XS
EoL-1-cell MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW3cpg2UUN3ME2wMlAxODBzM{Gg{txO Mm\wV2FPT0WU
CTV-1 M364OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXQNnd6UUN3ME2wMlAxODB2MESg{txO M4\scHNCVkeHUh?=
TE-15 NIq0NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLSXVdxUUN3ME2wMlAxPTh7IN88US=> MWjTRW5ITVJ?
NOS-1 NF25fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHaWJBKSzVyPUCuNFA3OTNizszN M{nwW3NCVkeHUh?=
D-336MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fiVGlEPTB;MD6wNFY{KM7:TR?= MVXTRW5ITVJ?
LB1047-RCC M1ziNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEC5PFkh|ryP NFvq[49USU6JRWK=
LB996-RCC M37Ocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3rSXlKSzVyPUCuNFA6QTFizszN NXHPPJcyW0GQR1XS
SW982 NFO4S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPaTWM2OD1yLkCxNVE2KM7:TR?= NXL0PW5NW0GQR1XS
TK10 M2TLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnnSWp{UUN3ME2wMlAyOTd2IN88US=> NFTscnNUSU6JRWK=
A704 M1LQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG4eG9KUUN3ME2wMlAyPDlzIN88US=> NIXXWWJUSU6JRWK=
TE-8 NI\yZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ixRWlEPTB;MD6wNVU4PiEQvF2= MkPqV2FPT0WU
DOHH-2 NXi2NoJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfnSFVKSzVyPUCuNFE4OTlizszN M2TpRXNCVkeHUh?=
HOP-62 M3fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEG4N|Qh|ryP NF[1OXZUSU6JRWK=
TE-12 NEe5Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn6S5lKSzVyPUCuNFE5PjFizszN NYLsbZV7W0GQR1XS
KGN M4DDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX5eVFKSzVyPUCuNFE6PDJizszN M2S5RXNCVkeHUh?=
NCI-H1648 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKyd2tKSzVyPUCuNFIxOTFizszN MoXtV2FPT0WU
OS-RC-2 NH3LZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfGTWM2OD1yLkCyNFMh|ryP Mmf0V2FPT0WU
GB-1 NHfJTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEKxOVch|ryP MVfTRW5ITVJ?
RXF393 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETw[2lKSzVyPUCuNFI{PTdizszN MXvTRW5ITVJ?
LC-2-ad NXGyfWgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPJVotJUUN3ME2wMlAzPTh4IN88US=> M2r0WHNCVkeHUh?=
KS-1 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17GbGlEPTB;MD6wNlc{KM7:TR?= M{D2OHNCVkeHUh?=
ETK-1 Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEK4N|Ih|ryP MVnTRW5ITVJ?
SW954 NUDZZ|g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jpbWlEPTB;MD6wNlkzPyEQvF2= NHjkd2dUSU6JRWK=
Becker M{j4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn22TWM2OD1yLkCzNFA{KM7:TR?= MWDTRW5ITVJ?
MZ1-PC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jwfWlEPTB;MD6wN|EyQSEQvF2= M2rvc3NCVkeHUh?=
ES6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrLTot{UUN3ME2wMlA{OTl|IN88US=> MXjTRW5ITVJ?
KURAMOCHI NHXFS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjMWXdKSzVyPUCuNFM1QDdizszN NH6zO2ZUSU6JRWK=
CGTH-W-1 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XuR2lEPTB;MD6wN|U1QCEQvF2= MlTYV2FPT0WU
VA-ES-BJ M37QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XlRmlEPTB;MD6wN|kxOiEQvF2= M4TjW3NCVkeHUh?=
LXF-289 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzkTWM2OD1yLkCzPVU3KM7:TR?= NHzaZWpUSU6JRWK=
MPP-89 NYDFS3Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWSwXIJDUUN3ME2wMlA1ODR7IN88US=> MUjTRW5ITVJ?
SW872 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTufZZtUUN3ME2wMlA1OTZzIN88US=> M4XPRXNCVkeHUh?=
SNB75 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL1bYdzUUN3ME2wMlA1PDN3IN88US=> Ml;QV2FPT0WU
PSN1 MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP3N5ZwUUN3ME2wMlA1PDd2IN88US=> M1Hq[3NCVkeHUh?=
LB831-BLC M{fucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;wbJNKSzVyPUCuNFQ3ODlizszN MoHYV2FPT0WU
MFH-ino NXHtOJFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fFXWlEPTB;MD6wOFczPCEQvF2= MVrTRW5ITVJ?
TGBC24TKB MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LuXmlEPTB;MD6wOFc3OSEQvF2= MoHhV2FPT0WU
A388 M1GwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzqXXZKSzVyPUCuNFUxQTVizszN Mn;vV2FPT0WU
BB30-HNC M2rSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXhTWM2OD1yLkC1OFM4KM7:TR?= NX\HPXNbW0GQR1XS
GI-ME-N NVXBOFhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfWVpNPUUN3ME2wMlA3OTF6IN88US=> NFm0RVVUSU6JRWK=
TGBC1TKB M3HPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwME[xOlQh|ryP M1nPUHNCVkeHUh?=
TE-10 M{CyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwME[zOVch|ryP MUPTRW5ITVJ?
A498 M1HM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqxfWpwUUN3ME2wMlA4Ojh2IN88US=> M1;hWXNCVkeHUh?=
TE-11 M1PSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL4V4tZUUN3ME2wMlA4QDV6IN88US=> MYHTRW5ITVJ?
BB65-RCC MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzqcnZKSzVyPUCuNFgzOjdizszN MkSyV2FPT0WU
C2BBe1 M3PJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TzXWlEPTB;MD6wPFMxQCEQvF2= M1XtPHNCVkeHUh?=
NCI-H747 NGKyPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEizOlIh|ryP M2PvUnNCVkeHUh?=
IST-MES1 M{XxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHTbIRKSzVyPUCuNFg2PTJizszN MV7TRW5ITVJ?
KALS-1 NEjZXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrNT3U6UUN3ME2wMlA6PDlizszN NGP1R5BUSU6JRWK=
GCIY NHzaOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLveVRKSzVyPUCuNFk3PTZizszN NE\3WJRUSU6JRWK=
RL95-2 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMUCzPEDPxE1? NXfnTo1PW0GQR1XS
TE-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zmPWlEPTB;MD6xNFU1KM7:TR?= NVHQZXQxW0GQR1XS
NCI-H1355 NUj1clNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUGwNlgh|ryP NWXEWXNzW0GQR1XS
SW962 NV60O2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvMfohKSzVyPUCuNVEzQTJizszN M1GycnNCVkeHUh?=
KLE NHjiNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXtTWM2OD1yLkGxN|E4KM7:TR?= NX;qSopFW0GQR1XS
MC116 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMUG0NUDPxE1? Mkn1V2FPT0WU
NMC-G1 MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\MTWM2OD1yLkGxOlA3KM7:TR?= NUDBWVJUW0GQR1XS
KU812 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\5fYZKSzVyPUCuNVE5QDNizszN M{TUdnNCVkeHUh?=
COLO-829 NVLq[YdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi0WnJpUUN3ME2wMlEzOjF|IN88US=> NFy0S4hUSU6JRWK=
NTERA-S-cl-D1 NVjxW5RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTVmlEPTB;MD6xNlI5OyEQvF2= M2fW[XNCVkeHUh?=
IST-MEL1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP2b4RKSzVyPUCuNVM1PSEQvF2= MlLMV2FPT0WU
MLMA MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOyZmpKSzVyPUCuNVQxOzJizszN MnyyV2FPT0WU
LS-123 MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\EbWlEPTB;MD6xOFA3PCEQvF2= M2r2ZXNCVkeHUh?=
LB2518-MEL M3vYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXOO4xKSzVyPUCuNVQyPjJizszN NEHrS25USU6JRWK=
NB69 NYn1bXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjiTWM2OD1yLkG0OFM3KM7:TR?= NVXKdFNDW0GQR1XS
8-MG-BA M3vZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G3UWlEPTB;MD6xOVQ2QCEQvF2= NVTIXFRZW0GQR1XS
K5 NFH5THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHDbVFKSzVyPUCuNVY1QDlizszN MWXTRW5ITVJ?
KINGS-1 M4rzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMU[2OlYh|ryP NV;NWFJ1W0GQR1XS
SF268 NYj4XJozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHUb5pMUUN3ME2wMlE4PDB2IN88US=> NFrxNlZUSU6JRWK=
PF-382 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfKdoUxUUN3ME2wMlE4Pjd6IN88US=> Mn:3V2FPT0WU
SH-4 NWiwR2ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMUi0NVMh|ryP M4DaXnNCVkeHUh?=
NALM-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPhTWM2OD1yLkG5Nlk2KM7:TR?= MYXTRW5ITVJ?
CP66-MEL Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUm1N|Eh|ryP NH;0UYpUSU6JRWK=
697 NHXKZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL6bWhKSzVyPUCuNVk6QDdizszN MmrIV2FPT0WU
CP67-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\5PJdKSzVyPUCuNlA1QDhizszN NEXFOHRUSU6JRWK=
DSH1 NV\IdmZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMkSwNFEh|ryP MX7TRW5ITVJ?
HCE-4 NF;wSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW5c5dKSzVyPUCuNlY1OzlizszN MmDYV2FPT0WU
MZ2-MEL M3LlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXuO49KSzVyPUCuNlg2OzdizszN M4LGeXNCVkeHUh?=
BL-41 NXHzdXBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;vWWR2UUN3ME2wMlI6OTJ|IN88US=> NIn4VVVUSU6JRWK=
HUTU-80 NXfSV2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLVUXIyUUN3ME2wMlMyPDJizszN NGjMZYhUSU6JRWK=
LOXIMVI NX3BZXlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\PSmlEPTB;MD6zNVUxOyEQvF2= M1vldXNCVkeHUh?=
no-10 NGfQOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwM{G5N|Eh|ryP NELhWYhUSU6JRWK=
KARPAS-422 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDPdplPUUN3ME2wMlM{QTl5IN88US=> MlHEV2FPT0WU
SW684 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fvZWlEPTB;MD6zOFk5KM7:TR?= M1zpUXNCVkeHUh?=
SF126 M{joV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xu[GlEPTB;MD6zOVQyKM7:TR?= M3PrcXNCVkeHUh?=
D-263MG MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\LTWM2OD1yLkO2NlI1KM7:TR?= MoTOV2FPT0WU
OVCAR-4 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwM{e0N|Mh|ryP MUjTRW5ITVJ?
BB49-HNC MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwM{i1PVkh|ryP NHG4VYhUSU6JRWK=
ONS-76 NYfzOJNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz0NGVKSzVyPUCuOFI6PTFizszN NFfuWHBUSU6JRWK=
MZ7-mel Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPWRndLUUN3ME2wMlQ4QTFzIN88US=> M{nWOXNCVkeHUh?=
RCC10RGB NHrLV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\6TWM2OD1yLkS5NVEh|ryP MnS2V2FPT0WU
BOKU NX;4NGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrnb4xKSzVyPUCuOFkyOzNizszN MlvxV2FPT0WU
no-11 M3HiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjO3hKSzVyPUCuOVAzOjhizszN NXK0dIxNW0GQR1XS
IST-SL2 NUT6W24xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[2TWM2OD1yLkWwN|AzKM7:TR?= NH3Y[I9USU6JRWK=
RKO NEXEcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnUTWM2OD1yLkWyPVY3KM7:TR?= NEPSTVFUSU6JRWK=
HT-144 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HC[WlEPTB;MD61N|YxQSEQvF2= MnP5V2FPT0WU
NCI-H446 NHLmOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Kz[GlEPTB;MD62Nlc3KM7:TR?= M1PUTXNCVkeHUh?=
QIMR-WIL M3vPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnMUIRKSzVyPUCuO|A3OjlizszN MX\TRW5ITVJ?
MHH-PREB-1 NVXYe3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:3TWM2OD1yLke0OFY6KM7:TR?= NHTIdGZUSU6JRWK=
EW-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPqTWM2OD1yLke2NVc5KM7:TR?= M2\2PXNCVkeHUh?=
EW-24 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[1TWM2OD1yLke4NVY2KM7:TR?= M2HOZ3NCVkeHUh?=
LB373-MEL-D NWnlbYFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwOEK1NFgh|ryP NGXxeIdUSU6JRWK=
TE-9 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7kb|FKSzVyPUCuPFc2OzJizszN M1P6fXNCVkeHUh?=
A3-KAW NVr4bJlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInYdndKSzVyPUCuPVg1PTJizszN MnKwV2FPT0WU
A101D Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrJb5FvUUN3ME2xMlA{ODR|IN88US=> NGr2Uo5USU6JRWK=
OCUB-M Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jJ[WlEPTB;MT6wOFQyOiEQvF2= MkjHV2FPT0WU
ES4 M4TZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke4TWM2OD1zLkC1NVQ2KM7:TR?= MnnPV2FPT0WU
TE-6 NVTadGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCwTWM2OD1zLkKxNlI3KM7:TR?= M2TiWHNCVkeHUh?=
D-502MG MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi0O4hKSzVyPUGuNlM{PzZizszN MXPTRW5ITVJ?
KNS-42 NF;y[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwMkS0NVIh|ryP Mmr0V2FPT0WU
SNU-C2B NYXRXVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Cb5pKSzVyPUGuN|A2QDlizszN NXLFS5hpW0GQR1XS
NCI-H1838 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DEb2lEPTB;MT6zNFc{OyEQvF2= MVjTRW5ITVJ?
NKM-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjzS4RwUUN3ME2xMlMxQDV7IN88US=> MlXxV2FPT0WU
GI-1 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3sbI5KSzVyPUGuN|YzOiEQvF2= MYDTRW5ITVJ?
NB5 M{GzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrBT5YzUUN3ME2xMlM6QDJ5IN88US=> NEDYR4RUSU6JRWK=
CAS-1 NIjFdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHDd2pKSzVyPUGuOFA6QTJizszN NHO0U2ZUSU6JRWK=
HCE-T Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vjOWlEPTB;MT61OlcyPCEQvF2= NHfl[HhUSU6JRWK=
SBC-1 NVHZV|hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\rZWpVUUN3ME2xMlU4QTh2IN88US=> MXvTRW5ITVJ?
JiyoyeP-2003 NF:y[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HWNWlEPTB;MT63N|Q3PiEQvF2= NGfhZ5JUSU6JRWK=
TE-5 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37sVWlEPTB;MT63PVE{QSEQvF2= NIL4SpFUSU6JRWK=
CAN M2rwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\BTWM2OD1zLkiyNlUzKM7:TR?= MofmV2FPT0WU
SK-UT-1 M3vuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLuTWM2OD1{LkG2Olk{KM7:TR?= NYHnN2V2W0GQR1XS
JVM-2 M2PDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHrTWM2OD1{LkO2Nlg1KM7:TR?= M2fnWHNCVkeHUh?=
LB771-HNC M3;tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTSTWM2OD1{LkW3OVUyKM7:TR?= MVjTRW5ITVJ?
NCCIT NILsXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwOE[2NVYh|ryP M13wSHNCVkeHUh?=
NCI-H2126 M3PlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3PT4JKSzVyPUKuPFc2PTJizszN NHTuXJlUSU6JRWK=
Calu-6 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPCUGtyUUN3ME2zMlA2PzRzIN88US=> M1v0N3NCVkeHUh?=
SK-LMS-1 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PoSmlEPTB;Mz6xNVg5PiEQvF2= NHj6V|BUSU6JRWK=
ARH-77 M3iwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf4bWNKSzVyPUOuOFY6OTVizszN NHTQO2RUSU6JRWK=
NB17 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j2ZmlEPTB;Mz62N|g1PyEQvF2= MorQV2FPT0WU
A253 M3e1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XIemlEPTB;Mz63N|I1PiEQvF2= MlHIV2FPT0WU
OPM-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\X[ZVwUUN3ME20MlI4Pjh3IN88US=> M{HTV3NCVkeHUh?=
MV-4-11 NECy[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTRwM{[0OVQh|ryP M3\CdnNCVkeHUh?=
SR NYXMSHZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwNEm5OVQh|ryP Mnn4V2FPT0WU
KG-1 NWHue4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfoV41lUUN3ME20MlYxQDR3IN88US=> NVvkRXJKW0GQR1XS
OCI-AML2 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXqTWM2OD13Lki2NVU1KM7:TR?= NI\aPJpUSU6JRWK=
D-247MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3x[G9KSzVyPU[uNVI2OTlizszN NFrPS29USU6JRWK=
DJM-1 NUTXbHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nHRWlEPTB;Nj60PFU2QCEQvF2= NULxS3M1W0GQR1XS
RPMI-6666 M3;vZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTdwMkewOlch|ryP M3y3NnNCVkeHUh?=
KARPAS-45 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrlZotnUUN3ME23MlUyPjdzIN88US=> Mn22V2FPT0WU
LP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zpNWlEPTB;Nz61OFc5OiEQvF2= MkGzV2FPT0WU
RS4-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XaS2lEPTB;Nz62OVc5PyEQvF2= NXTJcIVbW0GQR1XS
DU-4475 M1XjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;0T2E2UUN3ME24MlIyPjV{IN88US=> MnTGV2FPT0WU
MONO-MAC-6 NUPKb4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3QR2JKSzVyPUiuNlcxPjZizszN NEPBeHZUSU6JRWK=
NCI-SNU-16 NGHxVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jEcWlEPTB;OD61OlEzQCEQvF2= NGe0SYJUSU6JRWK=
SJSA-1 NFmzOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\COHhKSzVyPUiuO|I5ODVizszN NEPTfndUSU6JRWK=
MMAC-SF NWPaUWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\INWlEPTB;OD63PVMxPyEQvF2= NHnkO|ZUSU6JRWK=
SK-NEP-1 M{G0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOzVlRoUUN3ME24Mlg6OTV3IN88US=> NWS0dmhSW0GQR1XS
J-RT3-T3-5 MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS2NpRsUUN3ME24Mlk3PTJ7IN88US=> NITWTG1USU6JRWK=
SKM-1 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof6TWM2OD17LkCxO|M1KM7:TR?= NEP2OlJUSU6JRWK=
LB2241-RCC NGTWXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTlwMEKwNVIh|ryP MWrTRW5ITVJ?
SIG-M5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XMcGlEPTB;OT6wNlQ6OyEQvF2= M1\4eXNCVkeHUh?=
EVSA-T Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nNfmlEPTB;OT6yO|c6OyEQvF2= NGr1[pFUSU6JRWK=
GT3TKB NY\BT3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTlwM{W1OFYh|ryP MlPuV2FPT0WU
NB6 M1jv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TiRWlEPTB;OT65NlI2QSEQvF2= NIjTW3VUSU6JRWK=
EHEB M2fBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;MdWpNUUN3ME2xNE4xPjV4IN88US=> MVvTRW5ITVJ?
HEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUftSoVOUUN3ME2xNE41Pzd4IN88US=> Mnq0V2FPT0WU
ALL-PO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFyLke5N|gh|ryP NUHhXndXW0GQR1XS
TGW NYG3S5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPZd5JKSzVyPUGxMlI5OjhizszN NVHKdpVlW0GQR1XS
BC-3 NVPLV3VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz6U|BbUUN3ME2xNk4yOTN6IN88US=> NYjVbpE4W0GQR1XS
IA-LM NGjHZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjkbXRKSzVyPUGyMlQ1PDVizszN M2jHVnNCVkeHUh?=
UACC-257 NG\EV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7HSXhKSzVyPUGyMlkyQThizszN MYnTRW5ITVJ?
KP-N-YS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnCTWM2OD1zMj65Nlg{KM7:TR?= NFW4cJBUSU6JRWK=
Raji M1\sTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LPemlEPTB;MUOuO|Q6PyEQvF2= M1LFdnNCVkeHUh?=
SF539 NF7hS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF|Lki1OVch|ryP NF7GdnNUSU6JRWK=
DMS-153 M1e4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK1SGJWUUN3ME2xOE4xODJ6IN88US=> NXm2SG5kW0GQR1XS
L-540 NWPmfZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfacm5KSzVyPUG1MlA3PzJizszN M4D6U3NCVkeHUh?=
MN-60 M3;VNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF3LkG5O|kh|ryP NIn3Om9USU6JRWK=
RPMI-8866 M{P6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nJUWlEPTB;MUeuOFQ2PCEQvF2= MofZV2FPT0WU
NCI-H510A NHTXd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Kfo1HUUN3ME2xPU4{QTd|IN88US=> NHX4N2RUSU6JRWK=
NB13 NF\BTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkiwTWM2OD1zOT60PFc4KM7:TR?= MVHTRW5ITVJ?
HAL-01 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LaUmlEPTB;MUmuO|U1OyEQvF2= NYPJPIhUW0GQR1XS
NCI-H720 NUTtT5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[zPY5ZUUN3ME2yNE4zPzN|IN88US=> NGHsZXJUSU6JRWK=
REH NFz6bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJyLk[zOVch|ryP M3PkOXNCVkeHUh?=
KNS-81-FD M{DNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTwXm9UUUN3ME2yN{4yPDZizszN M3fq[XNCVkeHUh?=
HC-1 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ2LkW1OVEh|ryP Ml7XV2FPT0WU
NCI-H2141 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ2Lke3OVQh|ryP Ml60V2FPT0WU
MOLT-4 NE\iOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXsTWM2OD1{Nj62O|U{KM7:TR?= MXjTRW5ITVJ?
OMC-1 NH;5bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\1fJFKSzVyPUK3MlE1OjJizszN NH3EVo9USU6JRWK=
LC-1F NH\VdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ThNGlEPTB;MkeuN|I1PSEQvF2= NETMe|VUSU6JRWK=
NCI-H1304 M2e0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC0SYlOUUN3ME2yPE4yPjJ6IN88US=> MVHTRW5ITVJ?
BC-1 NHjFeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT6TWM2OD1{OD62OVEh|ryP NVvEenJLW0GQR1XS
NCI-H64 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS3NGFKSzVyPUK5MlYzPTNizszN NV3RUopZW0GQR1XS
MOLT-16 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ7Lk[yPVIh|ryP M3;jdnNCVkeHUh?=
U-87-MG NWjNZodPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHKNVFKSzVyPUOwMlc3PiEQvF2= NFS4TYJUSU6JRWK=
GAK NWDIW4xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6zV4VKSzVyPUOxMlI3QDZizszN MVfTRW5ITVJ?
ES8 NVriPWFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LFTmlEPTB;M{KuNVI2OiEQvF2= NGfFPWFUSU6JRWK=
HCC1599 NETHPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHkTWM2OD1|Mj6zN|I2KM7:TR?= MVjTRW5ITVJ?
EB-3 NYDHWpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN2LkOxNVch|ryP Ml7sV2FPT0WU
HCC1187 MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN3LkiwOVIh|ryP NUiyW|RKW0GQR1XS
SK-PN-DW NVHIWJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5Nlk5UUN3ME2zOk4yQTR|IN88US=> MkLUV2FPT0WU
JVM-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDUTWM2OD1|Nz6yN|M5KM7:TR?= M2jFcnNCVkeHUh?=
HCC2157 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTN5Lkm5OFYh|ryP MXvTRW5ITVJ?
A4-Fuk NVPKfpFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPsZphKSzVyPUO4MlExODlizszN M1XxeHNCVkeHUh?=
COR-L279 M1PMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDLTWM2OD12MD6yPFUyKM7:TR?= NFr3b3JUSU6JRWK=
DEL NFHhOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofKTWM2OD12MT65NFg3KM7:TR?= NFj3VlFUSU6JRWK=
NCI-H1395 NWXheplwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjPTWM2OD12Mj6wNVY{KM7:TR?= NFf4dHhUSU6JRWK=
MHH-NB-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\QTWM2OD12Mz6wPFE5KM7:TR?= M3TZWXNCVkeHUh?=
NCI-H2107 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTlSIJlUUN3ME20N{41QDR4IN88US=> M2[wSnNCVkeHUh?=
NEC8 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXkdXpKSzVyPUS0MlM{PiEQvF2= MlS4V2FPT0WU
COLO-684 NVHnRo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KVGlEPTB;NE[uNlI2QCEQvF2= NFTPNllUSU6JRWK=
LS-411N NWTyT5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPETWM2OD12OD60O|Q5KM7:TR?= NWTs[nc5W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Not yet recruiting Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic December 2019 Phase 1|Phase 2
NCT04115059 Not yet recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2
NCT03193281 Recruiting Drug: Dasatinib|Drug: Imatinib Chronic Myeloid Leukemia University of Auckland New Zealand|Leukaemia & Blood Cancer New Zealand July 17 2017 Phase 2
NCT03041701 Recruiting Drug: Dasatinib|Drug: Ganitumab Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID